Ventripoint Partners with Nisg̱a'a to Advance Cardiac Imaging in Remote Communities
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 12 2025
0mins
Should l Buy ABT?
Source: PRnewswire
- Innovative Collaboration: Ventripoint's partnership with Nisg̱a'a Valley Health Authority establishes a model that transforms standard 2D ultrasound images into MRI-level 3D models using the VMS+ system, significantly enhancing cardiac assessment capabilities in remote and Indigenous communities while reducing costs and eliminating the need for MRI scans.
- Technology Accessibility Plan: The collaboration employs a hub-and-spoke model where a central hub provides advanced cardiac capabilities to support remote healthcare, ensuring high-quality cardiac diagnostics are accessible even in isolated areas, thereby improving healthcare service availability.
- Future Expansion Vision: Ventripoint plans to extend this model to other First Nations communities across Canada and remote regions globally, including areas in the Amazon, Africa, and India, aiming to eliminate geographical barriers and ensure everyone has access to advanced diagnostic services.
- Management Change: Ventripoint appointed David Swetlow as CFO in October, bringing over 15 years of management experience from medical technology firms, which is expected to drive market adoption and revenue growth across international markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABT is 148.11 USD with a low forecast of 136.00 USD and a high forecast of 169.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 109.020
Low
136.00
Averages
148.11
High
169.00
Current: 109.020
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Reports 860 Serious Injuries and 7 Deaths Linked to Freestyle Libre 3 Sensors Recall by Abbott as of January 7
Injury and Fatality Report: The FDA has reported 860 serious injuries and 7 deaths associated with issues related to FreeStyle Libre 3 sensors.
Product Recall: The report highlights a recall of FreeStyle Libre 3 sensors due to safety concerns.
See More
FDA Classifies Abbott's Product Recall as Most Serious After Deaths
- Recall Severity: The FDA has classified Abbott Laboratories' (ABT) recall of certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors as the most serious type, following seven deaths and 860 serious injuries linked to faulty glucose readings, highlighting significant safety concerns surrounding the product.
- Health Impact on Patients: Abbott reported that inaccurate glucose readings from the faulty sensors could lead to incorrect clinical decisions for diabetes patients, potentially resulting in undetected long-term lower blood glucose levels, which poses a serious threat to patient health and safety.
- Patient Notification Actions: Abbott has informed affected patients through letters sent on November 25, ensuring they are aware of the recall and can take necessary actions, demonstrating the company's commitment to crisis management and patient safety.
- FDA Warnings and Recommendations: The FDA provided a link to the list of affected product lots and advised patients to immediately discontinue use of the FreeStyle Libre 3 sensors, emphasizing the regulatory body's proactive role in safeguarding public health.
See More
Healthcare Stocks Show Dividend Growth Potential
- AbbVie's Dividend Performance: AbbVie boasts a dividend yield of 2.98% and has increased its quarterly dividend for 54 consecutive years, raising it by 5.5% to $1.73 per share in 2023, demonstrating strong cash flow and consistent dividend growth capability.
- Strong Financial Performance: AbbVie reported third-quarter revenue of $15.8 billion, a 9% year-over-year increase, although earnings per share fell 38% to $1.86, its investments in oncology are expected to lay the groundwork for future growth and enhance market competitiveness.
- Medtronic's Market Position: Medtronic, the largest stand-alone medical device maker with a market cap of $132 billion, reported second-quarter revenue of $9 billion, up 6.6% year-over-year, and forecasts a 5.5% revenue increase in 2026, indicating sustained growth potential in the medical device sector.
- Sustainability of Dividend Growth: With dividend payout ratios of 58% for AbbVie and 69% for Medtronic, both companies maintain relatively high ratios; however, due to strong free cash flow and ongoing revenue growth, they are expected to sustain their dividend payments, bolstering investor confidence.
See More
AbbVie and Medtronic's Dividend Growth Potential
- AbbVie Dividend Performance: AbbVie boasts a dividend yield of 2.98% and has increased its quarterly dividend for 54 consecutive years, raising it by 5.5% to $1.73 per share in 2023, demonstrating strong cash flow and sustainable dividend growth potential.
- Medtronic Market Growth: In Q2 of fiscal 2026, Medtronic reported $9 billion in revenue, a 6.6% year-over-year increase, with EPS rising 8% to $1.07, and it anticipates a 5.5% revenue growth, showcasing its successful pivot into smart devices.
- Importance of R&D Investment: Both companies prioritize R&D, with AbbVie investing over $19 billion in 2023 to ensure ongoing product innovation, while Medtronic focuses on new product development to maintain competitiveness despite dividend payout pressures.
- Market Competitive Advantage: The size and diversification of AbbVie and Medtronic allow them to sustain revenue growth across various market segments, with AbbVie's oncology products accounting for 11% of its revenue and Medtronic planning to spin off its diabetes business to optimize resource allocation.
See More
Abbott Laboratories Reports Disappointing Q4 Results, Shares Decline
- Disappointing Performance: Abbott's Q4 sales reached $11.5 billion, a 4.4% increase year-over-year, but fell short of expectations, leading to a significant drop in stock price and highlighting challenges in its nutrition and diagnostics segments.
- Strong Medical Device Growth: Despite overall struggles, Abbott's medical device division achieved a 12.3% sales growth, with its diabetes care unit seeing a 14.5% revenue increase year-over-year, indicating ongoing growth potential in this sector.
- Acquisition for Growth: Abbott's planned $21 billion acquisition of cancer diagnostics leader Exact Sciences, known for its Cologuard test, is expected to provide a significant growth avenue for Abbott's diagnostics business, tapping into a rapidly expanding market.
- Attractive Dividend Stock: With 54 consecutive years of dividend increases, Abbott is classified as a Dividend King, currently offering a 2.20% yield, making it an appealing investment for those seeking stable income despite recent setbacks.
See More
Three Dividend Kings Worth Buying
- Abbott's Stability: Abbott Laboratories (ABT) has increased its dividend for 50 consecutive years, currently paying $2.52 per share with a yield of 2.4%, surpassing the S&P 500's 1.1%, indicating strong free cash flow and a diversified healthcare business that supports ongoing dividend payments.
- Target's Recovery Potential: Despite challenges like low-margin essential sales and theft, Target (TGT) is implementing turnaround strategies under new CEO Michael Fiddelke, which could drive stock recovery; with a dividend yield of 4.5%, it offers investors a reliable source of passive income.
- Johnson & Johnson's Growth Outlook: After spinning off its consumer health business, Johnson & Johnson (JNJ) focused on innovative medicine and medtech, achieving a 6% sales increase to over $94 billion last year, with adjusted EPS rising over 8%, indicating strong revenue growth potential and a dividend of $5.20 per share at a yield of 2.3%.
- Investment Value of Dividend Stocks: In the current market environment, dividend stocks like Abbott, Target, and Johnson & Johnson provide investors with a safe source of passive income, especially during market volatility, making them suitable for those seeking long-term stable returns.
See More
FDA Reports 860 Serious Injuries and 7 Deaths Linked to Freestyle Libre 3 Sensors Recall by Abbott as of January 7
Injury and Fatality Report: The FDA has reported 860 serious injuries and 7 deaths associated with issues related to FreeStyle Libre 3 sensors.
Product Recall: The report highlights a recall of FreeStyle Libre 3 sensors due to safety concerns.
See More
FDA Classifies Abbott's Product Recall as Most Serious After Deaths
- Recall Severity: The FDA has classified Abbott Laboratories' (ABT) recall of certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors as the most serious type, following seven deaths and 860 serious injuries linked to faulty glucose readings, highlighting significant safety concerns surrounding the product.
- Health Impact on Patients: Abbott reported that inaccurate glucose readings from the faulty sensors could lead to incorrect clinical decisions for diabetes patients, potentially resulting in undetected long-term lower blood glucose levels, which poses a serious threat to patient health and safety.
- Patient Notification Actions: Abbott has informed affected patients through letters sent on November 25, ensuring they are aware of the recall and can take necessary actions, demonstrating the company's commitment to crisis management and patient safety.
- FDA Warnings and Recommendations: The FDA provided a link to the list of affected product lots and advised patients to immediately discontinue use of the FreeStyle Libre 3 sensors, emphasizing the regulatory body's proactive role in safeguarding public health.
See More
Healthcare Stocks Show Dividend Growth Potential
- AbbVie's Dividend Performance: AbbVie boasts a dividend yield of 2.98% and has increased its quarterly dividend for 54 consecutive years, raising it by 5.5% to $1.73 per share in 2023, demonstrating strong cash flow and consistent dividend growth capability.
- Strong Financial Performance: AbbVie reported third-quarter revenue of $15.8 billion, a 9% year-over-year increase, although earnings per share fell 38% to $1.86, its investments in oncology are expected to lay the groundwork for future growth and enhance market competitiveness.
- Medtronic's Market Position: Medtronic, the largest stand-alone medical device maker with a market cap of $132 billion, reported second-quarter revenue of $9 billion, up 6.6% year-over-year, and forecasts a 5.5% revenue increase in 2026, indicating sustained growth potential in the medical device sector.
- Sustainability of Dividend Growth: With dividend payout ratios of 58% for AbbVie and 69% for Medtronic, both companies maintain relatively high ratios; however, due to strong free cash flow and ongoing revenue growth, they are expected to sustain their dividend payments, bolstering investor confidence.
See More
AbbVie and Medtronic's Dividend Growth Potential
- AbbVie Dividend Performance: AbbVie boasts a dividend yield of 2.98% and has increased its quarterly dividend for 54 consecutive years, raising it by 5.5% to $1.73 per share in 2023, demonstrating strong cash flow and sustainable dividend growth potential.
- Medtronic Market Growth: In Q2 of fiscal 2026, Medtronic reported $9 billion in revenue, a 6.6% year-over-year increase, with EPS rising 8% to $1.07, and it anticipates a 5.5% revenue growth, showcasing its successful pivot into smart devices.
- Importance of R&D Investment: Both companies prioritize R&D, with AbbVie investing over $19 billion in 2023 to ensure ongoing product innovation, while Medtronic focuses on new product development to maintain competitiveness despite dividend payout pressures.
- Market Competitive Advantage: The size and diversification of AbbVie and Medtronic allow them to sustain revenue growth across various market segments, with AbbVie's oncology products accounting for 11% of its revenue and Medtronic planning to spin off its diabetes business to optimize resource allocation.
See More
Abbott Laboratories Reports Disappointing Q4 Results, Shares Decline
- Disappointing Performance: Abbott's Q4 sales reached $11.5 billion, a 4.4% increase year-over-year, but fell short of expectations, leading to a significant drop in stock price and highlighting challenges in its nutrition and diagnostics segments.
- Strong Medical Device Growth: Despite overall struggles, Abbott's medical device division achieved a 12.3% sales growth, with its diabetes care unit seeing a 14.5% revenue increase year-over-year, indicating ongoing growth potential in this sector.
- Acquisition for Growth: Abbott's planned $21 billion acquisition of cancer diagnostics leader Exact Sciences, known for its Cologuard test, is expected to provide a significant growth avenue for Abbott's diagnostics business, tapping into a rapidly expanding market.
- Attractive Dividend Stock: With 54 consecutive years of dividend increases, Abbott is classified as a Dividend King, currently offering a 2.20% yield, making it an appealing investment for those seeking stable income despite recent setbacks.
See More
Three Dividend Kings Worth Buying
- Abbott's Stability: Abbott Laboratories (ABT) has increased its dividend for 50 consecutive years, currently paying $2.52 per share with a yield of 2.4%, surpassing the S&P 500's 1.1%, indicating strong free cash flow and a diversified healthcare business that supports ongoing dividend payments.
- Target's Recovery Potential: Despite challenges like low-margin essential sales and theft, Target (TGT) is implementing turnaround strategies under new CEO Michael Fiddelke, which could drive stock recovery; with a dividend yield of 4.5%, it offers investors a reliable source of passive income.
- Johnson & Johnson's Growth Outlook: After spinning off its consumer health business, Johnson & Johnson (JNJ) focused on innovative medicine and medtech, achieving a 6% sales increase to over $94 billion last year, with adjusted EPS rising over 8%, indicating strong revenue growth potential and a dividend of $5.20 per share at a yield of 2.3%.
- Investment Value of Dividend Stocks: In the current market environment, dividend stocks like Abbott, Target, and Johnson & Johnson provide investors with a safe source of passive income, especially during market volatility, making them suitable for those seeking long-term stable returns.
See More
